Hemophilia A
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Pfizer and Sangamo’s Gene Therapy Shows Superiority Over Prophylaxis in Hemophilia A Study
Pfizer, Sangamo, gene therapy, hemophilia A, prophylaxis, giroctocogene fitelparvovec, bleeding rate, Factor VIII
Pfizer’s Hemophilia A Gene Therapy Candidate Achieves Phase 3 Success
Pfizer, Hemophilia A, Gene Therapy, Phase 3 Trial, Giroctocogene Fitelparvovec, Bleeding Rate Reduction
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
Novel Monthly Hemophilia A Treatment by Novos Poses Challenge to Roche’s Hemlibra
Hemophilia A, Novos, Roche, Hemlibra, monthly treatment, performance, challenge.
Revolutionary Gene Therapy Advancements: Early Trial Results from Leading Biotech Companies
ASGCT24, gene therapy, early trial results, Freeline, Rocket, Creyon, biotech companies, genetic diseases, hemophilia, liver diseases, Parkinson’s disease.